Novo Nordisk's patent on semaglutide — the blockbuster diabetes and weight-loss drug marketed as Ozempic and Wegovy — expired in India on March 20-21, 2026, triggering one of the most crowded generic launches in Indian pharma history. Over 40 companies including Sun Pharma, Dr. Reddy's, Zydus, Lupin, Cipla and Natco Pharma launched or prepared generic versions. Natco's price starts at ₹1,290/month versus ₹8,800-16,400 for innovator drugs — a 70-90% reduction. India has approximately 101 million diabetes cases (ICMR 2023) and 254 million obese citizens. The generic versions make the cardiovascular risk-reducing drug accessible to millions who could not afford it previously.
Semaglutide Patent Expires in India; 40+ Pharma Companies Launch Generics at 70-90% Lower Prices
AQuick answer
Semaglutide patent expired in India; 40+ companies launched generics at ₹1,290/month vs ₹8,800-16,400 — a 70-90% price reduction.
Key facts
- Novo Nordisk's patent on semaglutide (marketed as Ozempic and Wegovy) expired in India on March 20-21, 2026.
- Over 40 companies including Sun Pharma, Dr. Reddy's, Zydus, Lupin, Cipla and Natco Pharma launched or prepared generic versions.
- Natco's generic price starts at ₹1,290/month versus ₹8,800-16,400 for innovator drugs — a 70-90% reduction.
- India has approximately 101 million diabetes cases (ICMR 2023) and 254 million obese citizens.
- Semaglutide is a blockbuster diabetes and weight-loss drug that also reduces cardiovascular risk.
Mains angle
Q: Discuss the public-health and industry implications of Novo Nordisk's semaglutide patent expiring in India on March 20-21, 2026.
Answer (50 words):
Novo Nordisk's patent on semaglutide, marketed as Ozempic and Wegovy, expired in India on March 20-21, 2026, triggering one of India's crowded generic launches. Over 40 firms including Sun Pharma, Dr. Reddy's, Zydus, Lupin, Cipla and Natco entered; Natco prices at ₹1,290 monthly versus ₹8,800-16,400 innovator pricing.
Static prep for this topic
Read the permanent syllabus behind this story.
Health, Food & NutritionScience & TechnologyIndustrial Growth & Economic ReformsIndian Economy
6-axis classification
CoverageNationalSubjectScience & TechnologyExamBasic Computer Instructor · CET Graduation · CET Senior Secondary · EO/RO · LDC · Mahila Supervisor · Patwar · PTI · RAS · REET · RPSC SI · School Lecturer · Senior Computer Instructor · Senior Teacher · UPSC · Vanpal · BothSourceBusiness Today
Appears in these topics
Practice MCQ from this story
SolveTap an option below. Correct or incorrect feedback appears instantly.
Linked questionMedium
How many pharma companies launched or prepared generic semaglutide after patent expiry in India?
Explanation · Correct answer A
Over 40 companies including Sun Pharma, Dr. Reddy's, Zydus, Lupin, Cipla and Natco launched or prepared generic semaglutide.
Source: Business Today
Frequently asked questions
When did the semaglutide patent expire in India and which companies launched generics?
**Novo Nordisk's** patent on **semaglutide** (marketed as **Ozempic** and **Wegovy**) expired in India on **March 20-21, 2026**. Over **40 companies** launched or prepared generic versions, including **Sun Pharma, Dr. Reddy's, Zydus, Lupin, Cipla, and Natco Pharma**, triggering one of the most crowded generic launches in Indian pharma history.
What is the price of generic semaglutide in India compared to the original Ozempic or Wegovy?
**Natco Pharma's** generic semaglutide starts at **₹1,290 per month**, compared to **₹8,800–16,400** for the innovator drugs **Ozempic** and **Wegovy** by Novo Nordisk — a reduction of **70–90%**. This drastic price drop follows the patent expiry on **March 20-21, 2026**, making the diabetes and weight-loss drug accessible to millions more Indians.
What diseases does semaglutide treat and why is it important for India?
**Semaglutide** is used to treat **Type 2 diabetes** and **obesity**, and also reduces **cardiovascular risk**. India has approximately **101 million diabetes cases** (ICMR 2023) and **254 million obese citizens**, making it one of the world's largest markets. The **70–90% price reduction** after patent expiry on **March 20-21, 2026** makes the drug accessible to millions who could not afford it.
How many pharma companies launched semaglutide generics in India after the patent expired?
Over **40 Indian pharmaceutical companies** launched or prepared generic versions of **semaglutide** after the **Novo Nordisk patent expired on March 20-21, 2026**. Major companies include **Sun Pharma, Dr. Reddy's, Zydus, Lupin, Cipla, and Natco Pharma**. Natco's version priced at **₹1,290/month** represents a **70–90% reduction** from the innovator brand price of ₹8,800–16,400.
What is Ozempic and Wegovy and who is the original manufacturer?
**Ozempic** and **Wegovy** are brand names for **semaglutide**, a blockbuster drug by **Novo Nordisk** (a Danish pharmaceutical company). Ozempic is used for **Type 2 diabetes management** while Wegovy is used for **weight loss**. Both also reduce cardiovascular risk. Their patents expired in India on **March 20-21, 2026**, enabling over **40 generic manufacturers** to launch affordable versions from **₹1,290/month**.
Was this useful?
Share corrections or missing exam angles with the editorial team.
Send feedback